NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
University of California, San Francisco
Amgen
Case Comprehensive Cancer Center
Celgene
Virginia Commonwealth University